A Phase 1 interventional study of lenvatinib and pembrolizumab (200 mg) in Hepatocellular Carcinoma, sponsored by Eisai Co., Ltd.. Completed at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.
Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 25th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 1, and was the 4th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 79 · Phase 3 17 · Phase 4 5
First in 2009; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 48 across the 121 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 121 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd.: none open now, 4 under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2017, is one of 6 in phase 1, and was the 8th registered.
Eisai Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2004.
14 of the studies testing lenvatinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT07081633AstraZenecaDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | 2026-11-30 |
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT06524466Sun Yat-sen UniversityNeoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | 2026-12-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, from their registry updates:
Among Eisai Co., Ltd.’s 20 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
Drug: lenvatinib · Drug: pembrolizumab (200 mg)
4 mg capsules
30-minute intravenous infusion
DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
Time frame: From first dose until 120 days after the last dose (up to 50.2 months)
Expansion Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE was defined as an AE that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
Time frame: From first dose until 120 days after the last dose (up to 50.2 months)
DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)
DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following: (1) any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; (2) failure to administer \>=75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; (3) participants who discontinued treatment due to treatment-related toxicity in Cycle 1; (4) greater than (\>) 2 week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity did not meet DLT criteria.
Time frame: From first dose of study drug up to Cycle 1 Day 21 (Cycle length= 21 days)
DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST and RECIST Version (v) 1.1 Assessed by Independent Imaging Review (IIR)
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by IIR analysis. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 millimeter \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the long diameter (LD) (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on mRECIST assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on RECIST v1.1 assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review
ORR was defined as the percentage of participants who had BOR of CR or PR based on mRECIST assessed by investigator review. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) based on mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Progression-free Survival (PFS) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review
PFS was defined as the time from the first study dose date to the date of first documentation of PD or death (whichever occurred first) based on mRECIST and RECIST v1.1 assessed by IIR, and mRECIST assessed by investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
Time frame: From the first study dose date to the date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
DLT+Expansion Part: Time-to-Progression (TTP) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review
TTP was defined as the time from the first study dose date to the date of first documentation of PD, based on mRECIST and RECIST v1.1 assessed by IIR and mRECIST assessed by an investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
Time frame: From date of first dose of study drug until PD (up to 46.2 months)
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)
DLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to RECIST v1.1 assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)
DLT+Expansion Part: Overall Survival (OS)
OS was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored at the date the participants were last known alive, whichever came earlier.
Time frame: From the date of first dose of study drug until date of death from any cause (up to 48.1 months)
DLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib
Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). As per pharmacokinetic (PK) planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib
Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib
AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, AUC(0-ti): Area Under The Plasma Concentration-time Curve From Zero (Pre-Dose) to a Given Sampling Time (ti) for Lenvatinib
AUC(0-ti) was defined as the area under the plasma concentration-time curve from 0 to a given sampling time for lenvatinib. AUC(0-ti) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib
AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib
t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib
Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib
Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib
Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib
AUC(0-tau) was defined as the area under the plasma concentration-time curve over dosing interval for lenvatinib. AUC(0-tau) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CLss/F was calculated as (Dose/AUC(0-tau))/F. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib
Css,Av was defined as the average plasma concentration at steady state for lenvatinib. Css,Av was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. Css,Av was calculated as AUC(0-tau)/tau. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and tau is the length of dosing interval. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib
Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz,ss/F was calculated as (CLss/F)/Lambda Z. Where, CLss/F is the apparent total clearance following oral administration at steady state and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib
Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib
Rac(AUC0-8 hour) was calculated as AUC(0-8 hour) at Cycle 1 Day 15/AUC(0-8 hour) at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib
The PTF within complete dosing interval at steady state, calculated as PTF (%) = (\[Css,max - Css,min\]/Css,Av)\* 100. Where, Css,max is the maximum observed plasma concentration at steady state and Css,min is the minimum observed plasma concentration at steady state and Css,Av average steady state plasma concentration. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
DLT+Expansion Part, Ctrough: Trough (Pre-dose) Serum Concentration for Pembrolizumab
Ctrough was defined as trough (pre-dose) serum concentration for pembrolizumab at steady state.
Time frame: Cycles 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36: Pre-dose (each Cycle length=21 days)
DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status
ADA positive was defined as participants with at least one pre-treatment or post-dose sample positive in the confirmatory assay for antibodies against pembrolizumab. ADA was assessed using a validated electrochemiluminescence (ECL) immunoassay.
Time frame: Cycles 1 and 6 Day 1: Pre-dose (each cycle length=21 days)
Participants took part in the study at 24 investigative sites in the United States, Japan, United Kingdom, France, Italy, Spain, and Russian Federation from 13 February 2017 to 22 November 2022.
| Milestone | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|---|
| Started | 6 | 98 |
| Japanese population | 6 | 16 |
| Non-japanese population | 0 | 82 |
| Completed | 6 | 0 |
| Not completed | 0 | 98 |
| Withdrew: Adverse event | 0 | 27 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Radiological disease progression | 0 | 52 |
| Withdrew: Clinical disease progression | 0 | 10 |
| Withdrew: Other | 0 | 8 |
A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
| Participants | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg |
|---|---|
| TEAEs | 6 |
| SAEs | 4 |
A TEAE was defined as an AE that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
| Participants | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| TEAEs | 97 |
| SAEs | 73 |
DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following: (1) any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; (2) failure to administer \>=75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; (3) participants who discontinued treatment due to treatment-related toxicity in Cycle 1; (4) greater than (\>) 2 week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity did not meet DLT criteria.
| Participants | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg |
|---|---|
| DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 |
ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by IIR analysis. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 millimeter \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the long diameter (LD) (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
| percentage of participants | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| RECIST v1.1 | 38.0 (28.5 to 48.3) |
| mRECIST | 46.0 (36.0 to 56.3) |
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on mRECIST assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR | 16.7 (8.6 to NA) |
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on RECIST v1.1 assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR | NA (12.6 to NA) |
ORR was defined as the percentage of participants who had BOR of CR or PR based on mRECIST assessed by investigator review. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
| percentage of participants | HCC 1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review | 43.0 (33.1 to 53.3) |
DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) based on mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review | 17.1 (6.9 to 19.3) |
PFS was defined as the time from the first study dose date to the date of first documentation of PD or death (whichever occurred first) based on mRECIST and RECIST v1.1 assessed by IIR, and mRECIST assessed by investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| mRECIST: IIR | 9.6 (5.6 to 11.8) |
| RECIST v1.1: IIR | 9.6 (7.6 to 10.8) |
| mRECIST: Investigator Review | 9.3 (7.4 to 9.8) |
TTP was defined as the time from the first study dose date to the date of first documentation of PD, based on mRECIST and RECIST v1.1 assessed by IIR and mRECIST assessed by an investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| mRECIST: IIR | 9.9 (9.3 to 20.0) |
| RECIST v1.1: IIR | 10.8 (9.6 to 24.3) |
| mRECIST: Investigator Review | 9.8 (7.7 to 15.9) |
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR | 2.5 (1.2 to 7.6) |
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to RECIST v1.1 assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR | 2.8 (1.2 to 13.8) |
TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review | 2.7 (1.2 to 15.7) |
OS was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored at the date the participants were last known alive, whichever came earlier.
| months | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| DLT+Expansion Part: Overall Survival (OS) | 20.4 (14.4 to 25.9) |
Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). As per pharmacokinetic (PK) planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| nanogram per milliliter (ng/mL) | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib | 127 ± 37.7 | 98.3 ± NA | 168 ± 29.7 | 145 ± 30.9 |
Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| hours | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib | 3.90 (1.00 to 7.97) | 4.00 (NA to NA) | 3.92 (0.82 to 7.92) | 4.00 (2.00 to 8.80) |
AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| nanogram*hour per milliliter (ng*h/mL) | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib | 1230 ± 7.61 | — | 1690 ± 23.7 | 1950 ± 39.2 |
AUC(0-ti) was defined as the area under the plasma concentration-time curve from 0 to a given sampling time for lenvatinib. AUC(0-ti) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng*h/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| Cycle 1 Day 1: 0-8 hours post-dose | 673 ± 29.3 | — | 868 ± 25.9 | 736 ± 42.2 |
| Cycle 1 Day 15: 0-8 hours post-dose | 793 ± 36.0 | — | 1020 ± 57.4 | 1120 ± 18.2 |
AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng*h/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| Cycle 1 Day 1: 0-24 hours post-dose | 1340 ± NA | — | 1900 ± 31.8 | 1540 ± 16.6 |
| Cycle 1 Day 15: 0-24 hours post-dose | — | — | 4690 ± NA | 2530 ± NA |
t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| hours | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| Cycle 1 Day 1: 0-24 hours post-dose | 7.71 ± NA | — | 6.64 ± 16.0 | 5.75 ± 3.07 |
| Cycle 1 Day 15: 0-24 hours post-dose | — | — | 7.33 ± NA | 6.48 ± NA |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| liter per hour (L/h) | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib | 5.98 ± NA | — | 6.32 ± 31.6 | 7.79 ± 16.7 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| liter | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib | 66.6 ± NA | — | 60.6 ± 23.2 | 64.7 ± 19.8 |
Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib | 154 ± 25.1 | 145 ± NA | 201 ± 53.5 | 193 ± 17.8 |
Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib | 42.9 ± 24.7 | 14.3 ± NA | 33.4 ± 48.1 | 34.3 ± 51.3 |
Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| hours | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib | 6.01 (4.00 to 8.00) | 4.02 (NA to NA) | 3.89 (2.02 to 7.77) | 4.00 (1.98 to 4.42) |
AUC(0-tau) was defined as the area under the plasma concentration-time curve over dosing interval for lenvatinib. AUC(0-tau) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng*h/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib | — | — | 4150 ± NA | 2330 ± 16.5 |
Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CLss/F was calculated as (Dose/AUC(0-tau))/F. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| L/h | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib | — | — | 2.89 ± NA | 5.14 ± 16.4 |
Css,Av was defined as the average plasma concentration at steady state for lenvatinib. Css,Av was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. Css,Av was calculated as AUC(0-tau)/tau. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and tau is the length of dosing interval. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ng/mL | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib | — | — | 173 ± NA | 97.2 ± 16.4 |
Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz,ss/F was calculated as (CLss/F)/Lambda Z. Where, CLss/F is the apparent total clearance following oral administration at steady state and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| liter | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib | — | — | 30.6 ± NA | 48.5 ± NA |
Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ratio | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib | 1.07 ± 28.6 | 1.48 ± NA | 1.17 ± 33.9 | 1.38 ± 41.7 |
Rac(AUC0-8 hour) was calculated as AUC(0-8 hour) at Cycle 1 Day 15/AUC(0-8 hour) at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| ratio | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib | 1.07 ± 21.2 | — | 1.32 ± 44.8 | 1.83 ± 66.8 |
The PTF within complete dosing interval at steady state, calculated as PTF (%) = (\[Css,max - Css,min\]/Css,Av)\* 100. Where, Css,max is the maximum observed plasma concentration at steady state and Css,min is the minimum observed plasma concentration at steady state and Css,Av average steady state plasma concentration. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.
| percentage fluctuation | DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mg | DLT+Expansion Part, Japanese Participants: Lenvatinib 12 mg | DLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg |
|---|---|---|---|---|
| DLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib | — | — | 161 ± NA | 161 ± 34.0 |
Ctrough was defined as trough (pre-dose) serum concentration for pembrolizumab at steady state.
| microgram per milliliter (mcg/mL) | DLT+Expansion Part: Pembrolizumab 200 mg |
|---|---|
| Cycle 1: Pre-dose | 0.00 ± 0.00 |
| Cycle 2: Pre-dose | 12.3 ± 40.7 |
| Cycle 4: Pre-dose | 21.9 ± 56.6 |
| Cycle 6: Pre-dose | 25.0 ± 64.7 |
| Cycle 8: Pre-dose | 26.6 ± 86.1 |
| Cycle 12: Pre-dose | 27.9 ± 57.7 |
| Cycle 16: Pre-dose | 33.6 ± 39.3 |
| Cycle 20: Pre-dose | 27.9 ± 50.1 |
| Cycle 24: Pre-dose | 29.0 ± 69.9 |
| Cycle 28: Pre-dose | 32.4 ± 49 |
| Cycle 32: Pre-dose | 30.7 ± 34.3 |
| Cycle 36: Pre-dose | 34.6 ± 40.2 |
ADA positive was defined as participants with at least one pre-treatment or post-dose sample positive in the confirmatory assay for antibodies against pembrolizumab. ADA was assessed using a validated electrochemiluminescence (ECL) immunoassay.
| Participants | HCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|
| Cycle 1 Day 1: Pre-dose | 3 |
| Cycle 6 Day 1: Pre-dose | 0 |
Collected over From the date of administration of the first dose of the study drug up to 120 days after the last dose of study drug (up to 50.2 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | 5/6 (83.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg | 67/98 (68.4%) | 73/98 (74.5%) | 97/98 (99%) |
| Event | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/6 | 2/98 |
| Inguinal herniaGastrointestinal disorders | 1/6 | 0/98 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 3/98 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 1/98 |
| Blood lactate dehydrogenase increasedInvestigations | 1/6 | 0/98 |
| Subarachnoid haemorrhageNervous system disorders | 1/6 | 0/98 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/98 |
| Blood bilirubin increasedInvestigations | 0/6 | 9/98 |
| Hepatic encephalopathyNervous system disorders | 0/6 | 6/98 |
| PyrexiaGeneral disorders | 0/6 | 5/98 |
| Event | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 6/6 | 37/98 |
| DiarrhoeaGastrointestinal disorders | 5/6 | 58/98 |
| HypothyroidismEndocrine disorders | 4/6 | 31/98 |
| Weight decreasedInvestigations | 4/6 | 33/98 |
| HypertensionVascular disorders | 4/6 | 46/98 |
| AnaemiaBlood and lymphatic system disorders | 3/6 | 28/98 |
| NauseaGastrointestinal disorders | 3/6 | 20/98 |
| Oedema peripheralGeneral disorders | 3/6 | 20/98 |
| Neutrophil count decreasedInvestigations | 3/6 | 8/98 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/6 | 0/98 |
The efficacy analysis set included all participants who had received at least 1 dose of study drug.
| Age, Continuous(years) | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg | Total |
|---|---|---|---|
| Mean | 65.2 ± 10.11 | 66.2 ± 8.16 | 66.1 ± 8.23 |
| Sex: Female, Male(Participants) | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg | Total |
|---|---|---|---|
| Female | 1 | 19 | 20 |
| Male | 5 | 79 | 84 |
| Ethnicity (NIH/OMB)(Participants) | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 6 | 78 | 84 |
| Unknown or Not Reported | 0 | 17 | 17 |
| Race (NIH/OMB)(Participants) | DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg | Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 26 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 0 | 51 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 19 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Oct 2019, 32 months.
Results were first posted in Dec 2020, 1 year 2 months after primary completion.
Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 32 months is below that.
Counting every sponsor, half of 248 studies reached it within 49 months; a quarter within 32 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Pembrolizumab